Biotechs - Transforming the future of healthcare
“Healthcare is all about innovation and biotech is the next tech,” says Dr Bianca Ogden, portfolio manager, Platinum International Health Care Fund.
Twenty years ago, when the human genome was first decoded, we saw the peak of interest in the biotech space. At the time, investing in biotech was considered akin to a weekend in Las Vegas. The years that followed were described by some as the dark days of biotech, as securing capital became difficult.
The biotech industry has navigated significant challenges in the past, but the COVID-19 pandemic has highlighted the maturity of the sector, bringing generalists back into the fold. We have been reminded that science can have a dramatic long-lasting effect. Polymerase Chain Reaction (PCR), a technique invented in early 1980s to amplify a segment of DNA, underpinned the biotech boom in late 1990s. Today, the same technology is used to detect SARS-CoV-2. In fact, PCR is a standard tool in every molecular biology lab globally. On the vaccine front, in less than a year, BioNTech/Pfizer and Moderna accomplished what most thought was impossible - developing a vaccine from scratch using mRNA technology.
These transformational technologies make biotech particularly exciting. We are not just referring to vaccines, but also protein engineering, gene editing, immunotherapies and innovation in diagnostics.
We believe that biotech companies should be considered alongside technology companies when considering investment opportunities. It is our strong belief that in the coming decade, biotech will transform the way healthcare is provided – it will have a profound impact on longevity and quality of life.
Dr Bianca Ogden from Platinum Asset Management shares her excitement and passion for biotechs in the short video below, please click on the picture.
We are very fortunate to have Dr Ogden present to us on Tuesday 16 March at 3pm - Beyond a vaccine - biotech an industry full of innovation.